Additionally, anti-CD138 CAR-T cells have shown promise in preclinical studies, and a phase 1 clinical trial is underway for patients with relapsed and refractory multiple myeloma (Clinical trial: NCT03672318). The gene discussed is SDC1; the disease is plasma cell myeloma.